|Bid||0.5500 x 25000|
|Ask||0.6000 x 3000|
|Day's Range||0.5504 - 0.5790|
|52 Week Range||0.1600 - 4.7500|
|PE Ratio (TTM)||-0.43|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).
On a per-share basis, the San Ramon, California-based company said it had a loss of 45 cents. Losses, adjusted to account for discontinued operations, came to 9 cents per share. In the final minutes of ...
Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.